Mesoblast saw the highest growth of 6.99% in patent filings in June and 2.99% in grants in April in Q2 2024. Compared to Q1 2024, Q2 2024 saw an increase in patent filings by 0.99% and grants by 2.99%. GlobalData’s DataBook provides a comprehensive analysis of Mesoblast‘s patent filings and grants. Buy the databook here.
Mesoblast has been focused on protecting inventions in South Korea(KR) with four publications in Q2 2024
The South Korea(KR) Patent Office dominates the patent filings and grants with nearly 15% filings and 67% grants. The United States(US), World Intellectual Property Organization(WIPO), South Korea(KR), and Japan(JP) patent Office are among the top ten patent offices where Mesoblast is filings its patents. Among the top granted patent authorities, Mesoblast has 67% of its grants in South Korea(KR) and 33% in Japan(JP).
Stanford University could be the strongest competitor for Mesoblast
Patents related to cell & gene therapy and rare diseases lead Mesoblast's portfolio
Mesoblast has the highest number of patents in cell & gene therapy followed by, rare diseases and Covid-19. For cell & gene therapy, nearly 47% of patents were filed and 50% of patents were granted in Q2 2024.
Inflammation related patents lead Mesoblast portfolio followed by acute respiratory distress syndrome, and congestive heart failure (heart failure)
Mesoblast has highest number of patents in inflammation followed by acute respiratory distress syndrome, congestive heart failure (heart failure), graft versus host disease (gvhd), and coronavirus disease 2019 (covid-19). For inflammation, nearly 9% of patents were filed and 25% of patents were granted in Q2 2024.
For comprehensive analysis of Mesoblast's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.